Sanara MedTech (NASDAQ:SMTI) Shares Up 2.9% – Time to Buy?

Shares of Sanara MedTech Inc. (NASDAQ:SMTI) rose 2.9% on Wednesday . The stock traded as high as $19.75 and last traded at $19.65. Approximately 85,287 shares were traded during mid-day trading, an increase of 22% from the average daily volume of 70,159 shares. The stock had previously closed at $19.09.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday, January 22nd. Zacks Research downgraded shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Wall Street Zen lowered shares of Sanara MedTech from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Sanara MedTech in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sanara MedTech presently has an average rating of “Hold” and a consensus price target of $41.00.

Sanara MedTech Trading Up 2.9%

The company has a current ratio of 1.80, a quick ratio of 1.60 and a debt-to-equity ratio of 7.34. The stock has a market cap of $174.89 million, a P/E ratio of -4.66 and a beta of 1.01. The business’s fifty day simple moving average is $22.59 and its 200 day simple moving average is $26.54.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Stonebridge Wealth Management LLC bought a new stake in shares of Sanara MedTech during the second quarter worth $3,397,000. Stephens Inc. AR increased its position in Sanara MedTech by 18.0% in the second quarter. Stephens Inc. AR now owns 12,794 shares of the company’s stock worth $363,000 after purchasing an additional 1,952 shares during the period. Wells Fargo & Company MN raised its holdings in Sanara MedTech by 78.1% during the 4th quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock worth $78,000 after purchasing an additional 1,457 shares during the last quarter. Jane Street Group LLC acquired a new position in Sanara MedTech during the 4th quarter valued at about $355,000. Finally, Deutsche Bank AG boosted its stake in shares of Sanara MedTech by 171.1% in the 4th quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock valued at $93,000 after purchasing an additional 2,515 shares during the last quarter. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.